Will Pharmasset’s $11 Billion Windfall Benefit Other HCV Players?
Executive Summary
Gilead Sciences’ offer of $11 billion for Pharmasset shattered all previous records for the cost of buying out a clinical-stage biotech and further cemented the status of hepatitis C as one of the hottest spaces in biopharmaceutical development.